Solid result.A summary of the results are as follows:
• 40.0% increase in Revenue to $96.7m
• 44.7% increase in EBITDA to $35.3m
• 44.4% increase in NPAT to $20.1m
• 27.1% increase in Gross Loans Receivable to $198.8m
With the recent securing of debt, we are well funded to build on the existing growth momentum the business is experiencing and we look forward to an exciting financial year 2017."
Good idea to cut the dividend, and accelerate the growth profile. I love the outlook statement. No hype, no fuss ... just telling us what to expect in a just a few words.....
Outlook
Money3 continues to experience strong growth momentum and expects to achieve NPAT of $26m for FY17.
-
- Forums
- ASX - By Stock
- Ann: Full Year Results Announcement-MNY.AX
Solid result. A summary of the results are as follows: • 40.0%...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.30 |
Change
-0.040(3.00%) |
Mkt cap ! $265.2M |
Open | High | Low | Value | Volume |
$1.35 | $1.35 | $1.28 | $88.11K | 68.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7018 | $1.29 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.32 | 3751 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7018 | 1.285 |
1 | 5169 | 1.260 |
3 | 2641 | 1.250 |
3 | 19875 | 1.240 |
1 | 809 | 1.235 |
Price($) | Vol. | No. |
---|---|---|
1.315 | 3751 | 1 |
1.345 | 20000 | 1 |
1.350 | 104093 | 3 |
1.355 | 7500 | 1 |
1.360 | 112895 | 3 |
Last trade - 16.10pm 13/11/2024 (20 minute delay) ? |
Featured News
SVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online